Please login to the form below

I have forgotten my password

CRPC

This page shows the latest CRPC news and features for those working in and with pharma, biotech and healthcare.

AZ/Merck's Lynparza improves survival in certain prostate cancers

CRPC, and a 52% prostate-specific antigen (PSA) response.

Latest news

Exelixis bounces back with new prostate cancer data

The COSMIC-021 trial evaluated the combination treatment in patients with locally advanced or metastatic castration-resistant prostate cancer (CRPC), whose disease had progressed on prior novel hormone therapy. ... Exelixis intends to file the
Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer

First approval could give Clovis an opportunity to build familiarity with its brand among clinicians treating CRPC before its big pharma rivals reach the market, although its rivals are hot on ... the first half of 2020, while GSK/J&J have also reported
Pfizer raises forecast following growth of biopharma business

For Pfizer, the potential approval in this indication could help drive Xtandi's growth even further – the drug picked up an approval in castration-resistant prostate cancer (CRPC) with non-metastatic ... CRPC last year.
J&J puts pressure on rivals with new Erleada okay in prostate cancer

Meanwhile, Zytiga – which is only approved for metastatic CRPC – pulled in $3.5bn last year, but the start of generic competition in late 2018 was evident in a 21% slump in
Trial backs role for Lynparza in second-line prostate cancer

subpopulation of HRRms – namely BRCA1/BRCA2 and ATM mutations – and that makes PROfound “the only positive phase 3 trial of any PARP inhibitor” in CRPC. ... AZ is also conducting a phase 3 trial (PROPEL) of Lynparza in combination with Zytiga as

More from news
Approximately 1 fully matching, plus 42 partially matching documents found.

Latest Intelligence

Drug launches to watch in 2019

In patients with non-metastatic CRPC, there is a high unmet need to delay development of metastases and the progression to advanced prostate cancer. ... for approval in the US and EU for non-metastatic CRPC on the strength of MFS data from the PROSPER

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Account Management: Competitive Salary Offered

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Senior Content Editor - Biotechnology: Salary TBC

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

PMHub

Add my company

Langland

Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...

Latest intelligence

Want to give perfect client service? Tough luck, you’re human: In this article an ex-client of mine, Liz Skrbkova, and I explore the (unhelpful) pressures of trying to perfect the client-agency relationship...
WHITE PAPER: Why do men die younger?: It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials: Here are some useful tips to help get your hands on authentically diverse stock photos....